Exelixis, Inc. (EXEL)
Largest Insider Buys in Sector
EXEL Stock Price History Chart
EXEL Stock Performance
About Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, …
Insider Activity of Exelixis, Inc.
Over the last 12 months, insiders at Exelixis, Inc. have bought $12.67M and sold $24.87M worth of Exelixis, Inc. stock.
On average, over the past 5 years, insiders at Exelixis, Inc. have bought $7.63M and sold $25.93M worth of stock each year.
Highest buying activity among insiders over the last 12 months: JOHNSON DAVID EDWARD (director) — $38M.
The last purchase of 225,000 shares for transaction amount of $4.67M was made by JOHNSON DAVID EDWARD (director) on 2024‑05‑30.
List of Insider Buy and Sell Transactions, Exelixis, Inc.
| 2024-11-29 | Sale | EVP & General Counsel | 60,000 0.0211% | $36.67 | $2.2M | -3.29% | ||
| 2024-11-22 | Sale | EVP, Commercial | 10,000 0.0035% | $35.27 | $352,700 | -0.06% | ||
| 2024-11-18 | Sale | EVP, Commercial | 41,588 0.0145% | $34.36 | $1.43M | +1.19% | ||
| 2024-11-05 | Sale | CSO/EVP Disc & Trans Research | 96,986 0.0346% | $35.00 | $3.39M | +0.41% | ||
| 2024-11-01 | Sale | EVP & General Counsel | 50,000 0.0175% | $34.13 | $1.71M | +4.19% | ||
| 2024-11-01 | Sale | director | 30,000 0.0105% | $34.00 | $1.02M | +4.19% | ||
| 2024-10-30 | Sale | CSO/EVP Disc & Trans Research | 1,162 0.0004% | $31.40 | $36,487 | +9.32% | ||
| 2024-10-28 | Sale | EVP & General Counsel | 25,000 0.0086% | $28.39 | $709,750 | +6.46% | ||
| 2024-09-23 | Sale | EVP & General Counsel | 25,000 0.0088% | $26.38 | $659,500 | +31.45% | ||
| 2024-08-26 | Sale | EVP, General Counsel & Sec | 20,000 0.007% | $25.79 | $515,800 | +12.32% | ||
| 2024-08-14 | Sale | director | 8,250 0.0028% | $26.56 | $219,120 | 0.00% | ||
| 2024-08-12 | Sale | CSO/EVP Disc & Trans Research | 20,883 0.0073% | $27.06 | $565,094 | +5.83% | ||
| 2024-08-09 | Sale | EVP and CFO | 125,000 0.0442% | $27.19 | $3.4M | +4.00% | ||
| 2024-08-08 | Sale | director | 33,725 0.0115% | $26.89 | $906,865 | +1.58% | ||
| 2024-08-07 | Sale | EVP, General Counsel & Sec | 80,000 0.0269% | $25.97 | $2.08M | +3.83% | ||
| 2024-08-07 | Sale | CSO/EVP Disc & Trans Research | 95,000 0.0307% | $25.00 | $2.38M | +3.83% | ||
| 2024-08-07 | Sale | EVP, Commercial | 14,000 0.0046% | $25.50 | $357,000 | +3.83% | ||
| 2024-06-04 | Sale | director | 8,287 0.0029% | $22.00 | $182,314 | +21.29% | ||
| 2024-05-30 | director | 225,000 0.0772% | $20.76 | $4.67M | +26.61% | |||
| 2024-05-28 | director | 200,000 0.0686% | $20.32 | $4.06M | +29.48% |
Insider Historical Profitability
| JOHNSON DAVID EDWARD | director | 1525730 0.5343% | $33.29 | 4 | 1 | |
| PAPADOPOULOS STELIOS | director | 1260578 0.4414% | $33.29 | 2 | 11 | +117.05% |
| SCANGOS GEORGE A | director | 714717 0.2503% | $33.29 | 1 | 243 | +51.69% |
| Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | 614078 0.215% | $33.29 | 1 | 37 | +9.5% |
| WILLSEY LANCE | 424415 0.1486% | $33.29 | 12 | 12 | +142.31% |
Institutional Investor Ownership
| BlackRock | $827.76M | 11.98 | 34.88M | -3.14% | -$26.86M | 0.02 | |
| The Vanguard Group | $731.35M | 10.58 | 30.82M | -2.69% | -$20.2M | 0.01 | |
| Farallon Capital | $633.08M | 9.16 | 26.68M | +0.17% | +$1.04M | 4.45 | |
| Renaissance Technologies | $358.36M | 5.18 | 15.1M | -3.29% | -$12.2M | 0.57 | |
| State Street | $310.42M | 4.49 | 13.08M | +0.37% | +$1.15M | 0.01 |